Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.

Trial Details

NCT ID
NCT03769129
Phase
NA
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pembrolizumab
  • microwave ablation
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Pathologically diagnosed IIIB or IV non-small cell lung cancer.
  • Previously accepted first-line standard treatment failure or recurrence
  • At least one measurable lesion.
  • The patient has not received any other anti-cancer treatment within four weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →